Profound Medical reports Q3 EPS (26c), consensus (38c)

Reports Q3 revenue $5.29M, consensus $4.98M. “The theme of my presentation at the Stifel Healthcare Conference earlier this week was ‘It’s Happening!’,” said Arun Menawat, Profound’s CEO and chairman. “As demonstrated by our strong revenue and TULSA Procedure volume growth, increased gross margin, improved bottom line, and rapidly expanding TULSA-PRO installed base, we were not only able to successfully navigate through an unusually challenging second quarter, but also delivered record results in Q3-2025. So far, that positive momentum has continued into the fourth quarter, and we look forward to updating investors as we progress.”